Revenio Group Corporation: Mikko Moilanen appointed as Revenio's CEO

Stock Exchange Release, 15.4.2019 at 9.30 am EET

Insider information 15.4.2019, at 9:30 EET


M.Sc. (EE) Mikko Moilanen, (b. 1965) has been appointed as the CEO of Revenio Group Corporation and Revenio’s Group company Icare Finland Oy. He will assume the position at the latest on October 14, 2019, or possibly earlier. Revenio’s current CEO Timo Hildén moves at his own request, initially along with the CEO's duties and later full-time, to lead the integration work of CenterVue acquisition and he will also support Mikko Moilanen in taking over the CEO’s responsibilities.

Mikko Moilanen has earlier worked as the CEO of Grano Group Oy, owned by the investment company Panostaja Oyj, as the CEO of Suunto Oy and he has held several international management positions in Nokia Plc. He has extensive experience and strong track record in leading technology companies and expert organizations in international business environment.

Through is his experience Mikko is familiar with European, American and Asian markets both within consumer and B2B business and has strong experience of leadership in innovative and R&D driven corporate cultures.

Revenio Group’s Chairman of the Board Pekka Rönkä comments:

”As Timo Hildén expressed his wish to focus on completing and integrating the CenterVue acquisition that he initiated, it was a major task for the Board of Directors to find the best possible successor for him. I am extremely pleased that we have just Mikko Moilanen to lead Revenio to the next phase of growth. Mikko has extensive experience both in growth management and international businesses as well as distributor networks and large customer co-operation. As a leader, he is experienced, honest, and make-things-happen kind of a person - easy to approach and available. On behalf of myself and the entire Board of the Revenio Group I wish Mikko warmly welcome to steer the successful teams of Revenio and Icare towards the next phase.”

Mikko Moilanen comments:

”For me Revenio, Icare and health technology represent an international industry with enormous potential, characterized by innovation and deep expertise. I take on the responsibilities of the CEO with great interest and I believe I will bring a new perspective to the company through my experience and leadership. As a leader, it is my important task to support and create the conditions for the growth and development of both the organization and the individuals. I very much look forward to working with my team to start building us a common future.”

Revenio Group Corporation

Board of Directors

For further information, please contact:

Chairman of the Board Pekka Rönkä, tel. +358 40 826 4356

Mikko Moilanen, tel. +358 400 742 559


Nasdaq Helsinki

Financial Supervisory Authority

Principal media

The Revenio Group in brief

Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology.

The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy. Revenio’s core business is to develop and commercialize effective and easily adopted devices to assist in the diagnostics of glaucoma and its monitoring during treatment.

Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio’s technology is on the early detection of glaucoma, skin cancer and asthma, and the monitoring of these during the treatment process.

In 2018, the Revenio Group's net sales totaled EUR 30.7 million, with its operating margin standing at 33.3%. Revenio Group Corporation is listed on Nasdaq Helsinki.